Last reviewed · How we verify
TICE®-strain BCG
At a glance
| Generic name | TICE®-strain BCG |
|---|---|
| Also known as | BCG Live, Tice® BCG, BCG Vaccine |
| Sponsor | Ludwig Institute for Cancer Research |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
- Gastroesophageal reflux disease
- Injection site reaction
- Blood calcium decreased
- Dyspnea
- Fatigue
- Perineal pain
- Peripheral edema
Key clinical trials
- Vaccine Therapy in Treating Patients With Transitional Cell Carcinomas (PHASE1)
- BCG Vaccination to Prevent COVID-19 (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TICE®-strain BCG CI brief — competitive landscape report
- TICE®-strain BCG updates RSS · CI watch RSS
- Ludwig Institute for Cancer Research portfolio CI